Arena Rises With Post-Belviq Pipeline

Arena's valuation rose more than four-fold in 2017. CEO Amit Munshi discusses his plans for lead programs ralinepag and etrasimod following cost cutting and fundraising, and handing over rights to weight loss product Belviq to Eisai.

Video interview
Interview with Arena CEO Amit Munshi

Amit Munshi joined Arena Pharmaceuticals Inc. as CEO in 2016 to turn the company around. He negotiated the handing over of rights to the weight loss product Belviq (lorcaserin) to partner Eisai Co. Ltd. , and set about refocusing the business on its lead programs ralinepag and etrasimod. (Also see "Beyond Belviq: Reinventing Arena To Focus On Phase II Candidates" - Scrip, 7 February, 2017.)

Cutting out costs of $100m and raising $270m from institutional investors, Arena saw its valuation rise from about $350m to some $1.6bn in 2017

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

More from Business